Literature DB >> 25689347

Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.

Ribai Yan1, Hsiao-Ching Chuang, Naval Kapuriya, Chih-Chien Chou, Po-Ting Lai, Hsin-Wen Chang, Chia-Ning Yang, Samuel K Kulp, Ching-Shih Chen.   

Abstract

Previously, we reported that Akt inactivation by γ-tocopherol (2) in PTEN-negative prostate cancer cells resulted from its unique ability to facilitate membrane co-localization of Akt and PHLPP1 (PH domain leucine-rich repeat protein phosphatase isoform 1), a Ser473-specific Akt phosphatase, through pleckstrin homology (PH) domain binding. This finding provided a basis for exploiting 2 to develop a novel class of PHLPP1-targeted Akt inhibitors. Here, we used 3 (γ-VE5), a side chain-truncated 2 derivative, as a scaffold for lead optimization. The proof-of-concept of this structural optimization was obtained by 20, which exhibited higher antitumor efficacy than 3 in PTEN-negative cancer cells through PHLPP1-facilitated Akt inactivation. Like 3, 20 preferentially recognized the PH domains of Akt and PHLPP1, as its binding affinities for other PH domains, including those of ILK and PDK1, were an order-of-magnitude lower. Moreover, 20 was orally active in suppressing xenograft tumor growth in nude mice, which underlines the translational potential of this new class of Akt inhibitor in PTEN-deficient cancers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25689347      PMCID: PMC4720140          DOI: 10.1021/jm501751b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  PHLPPing it off: phosphatases get in the Akt.

Authors:  Michelle C Mendoza; John Blenis
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

3.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

Authors:  Yan Luo; Alexander R Shoemaker; Xuesong Liu; Keith W Woods; Sheela A Thomas; Ron de Jong; Edward K Han; Tongmei Li; Vincent S Stoll; Jessica A Powlas; Anatol Oleksijew; Michael J Mitten; Yan Shi; Ran Guan; Thomas P McGonigal; Vered Klinghofer; Eric F Johnson; Joel D Leverson; Jennifer J Bouska; Mulugeta Mamo; Richard A Smith; Emily E Gramling-Evans; Bradley A Zinker; Amanda K Mika; Phong T Nguyen; Tilman Oltersdorf; Saul H Rosenberg; Qun Li; Vincent L Giranda
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

4.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

Authors:  Craig W Lindsley; Zhijian Zhao; William H Leister; Ronald G Robinson; Stanley F Barnett; Deborah Defeo-Jones; Raymond E Jones; George D Hartman; Joel R Huff; Hans E Huber; Mark E Duggan
Journal:  Bioorg Med Chem Lett       Date:  2005-02-01       Impact factor: 2.823

5.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

6.  Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.

Authors:  Zhijian Zhao; William H Leister; Ronald G Robinson; Stanley F Barnett; Deborah Defeo-Jones; Raymond E Jones; George D Hartman; Joel R Huff; Hans E Huber; Mark E Duggan; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

7.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.

Authors:  John Brognard; Emma Sierecki; Tianyan Gao; Alexandra C Newton
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

8.  Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues.

Authors:  S Sianna Castillo; John Brognard; Pavel A Petukhov; Chunyu Zhang; Junji Tsurutani; Courtney A Granville; Min Li; Michael Jung; Kip A West; Joell G Gills; Alan P Kozikowski; Phillip A Dennis
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

9.  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.

Authors:  Stanley F Barnett; Deborah Defeo-Jones; Sheng Fu; Paula J Hancock; Kathleen M Haskell; Raymond E Jones; Jason A Kahana; Astrid M Kral; Karen Leander; Ling L Lee; John Malinowski; Elizabeth M McAvoy; Debbie D Nahas; Ronald G Robinson; Hans E Huber
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

10.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Authors:  Sudhir B Kondapaka; Sheo S Singh; Girija P Dasmahapatra; Edward A Sausville; Krishnendu K Roy
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.